Your browser doesn't support javascript.
loading
A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.
Abrego, Jaime; Sanford-Crane, Hannah; Oon, Chet; Xiao, Xu; Betts, Courtney B; Sun, Duanchen; Nagarajan, Shanthi; Diaz, Luis; Sandborg, Holly; Bhattacharyya, Sohinee; Xia, Zheng; Coussens, Lisa M; Tontonoz, Peter; Sherman, Mara H.
Afiliación
  • Abrego J; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
  • Sanford-Crane H; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
  • Oon C; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
  • Xiao X; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Betts CB; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
  • Sun D; Computational Biology Program, Oregon Health & Science University, Portland, Oregon.
  • Nagarajan S; Medicinal Chemistry Core, Oregon Health & Science University, Portland, Oregon.
  • Diaz L; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
  • Sandborg H; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
  • Bhattacharyya S; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
  • Xia Z; Computational Biology Program, Oregon Health & Science University, Portland, Oregon.
  • Coussens LM; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
  • Tontonoz P; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
  • Sherman MH; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Cancer Discov ; 12(10): 2414-2433, 2022 10 05.
Article en En | MEDLINE | ID: mdl-35894778
Despite significant recent advances in precision medicine, pancreatic ductal adenocarcinoma (PDAC) remains near uniformly lethal. Although immune-modulatory therapies hold promise to meaningfully improve outcomes for patients with PDAC, the development of such therapies requires an improved understanding of the immune evasion mechanisms that characterize the PDAC microenvironment. Here, we show that cancer cell-intrinsic glutamic-oxaloacetic transaminase 2 (GOT2) shapes the immune microenvironment to suppress antitumor immunity. Mechanistically, we find that GOT2 functions beyond its established role in the malate-aspartate shuttle and promotes the transcriptional activity of nuclear receptor peroxisome proliferator-activated receptor delta (PPARδ), facilitated by direct fatty acid binding. Although GOT2 is dispensable for cancer cell proliferation in vivo, the GOT2-PPARδ axis promotes spatial restriction of both CD4+ and CD8+ T cells from the tumor microenvironment. Our results demonstrate a noncanonical function for an established mitochondrial enzyme in transcriptional regulation of immune evasion, which may be exploitable to promote a productive antitumor immune response. SIGNIFICANCE: Prior studies demonstrate the important moonlighting functions of metabolic enzymes in cancer. We find that the mitochondrial transaminase GOT2 binds directly to fatty acid ligands that regulate the nuclear receptor PPARδ, and this functional interaction critically regulates the immune microenvironment of pancreatic cancer to promote tumor progression. See related commentary by Nwosu and di Magliano, p. 2237.. This article is highlighted in the In This Issue feature, p. 2221.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / PPAR delta Límite: Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / PPAR delta Límite: Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article